Bristol Myers Squibb and Erasca Partner to Evaluate Combination Therapy for Pancreatic Cancer

Bristol Myers Squibb (BMY) has entered into a collaborative arrangement with Erasca (ERAS) to study the efficacy of navlimetostat in combination with ERAS-0015. The clinical evaluation will focus on treating pancreatic ductal adenocarcinoma, which is the most prevalent form of pancreatic cancer. Under the agreement, Erasca will provide ERAS-0015, a drug candidate described as a potentially best-in-class pan-RAS molecular glue. This partnership aims to leverage the combined therapeutic potential of both assets to address high unmet needs in oncology patients.

By https://seekingalpha.com/user/53161691/bio · Seeking Alpha ·

Bristol Myers Squibb and Erasca Partner to Evaluate Combination Therapy for Pancreatic Cancer

Tickers: $BMY $ERAS

Topics: biotechnology drug development oncology pancreatic cancer

Read the full article at Seeking Alpha

Part of the story Bristol Myers Squibb Reports Positive Phase 3 Data for Alzheimer's Psychosis Treatment KarXT (2 articles)

More World news